Periprocedural management of patients on long-term warfarin therapy remains a common and important clinical issue, with little high-quality data to guide this complex process. The current accepted practice is cessation of warfarin five days preoperatively, but this is not without risk and can be complicated, particularly if bridging is required. An alternative method utilising low-dose intravenous vitamin K the day before surgery has been shown previously to be efficacious, safe and convenient in an elective surgical population receiving chronic warfarin therapy. The efficacy and utility of this 'fast-track' warfarin reversal protocol in surgical patients with cancer, who were at high risk of both thromboembolism and bleeding was investigated in a prospective, single-arm study at a dedicated cancer centre. Seventy-one patients underwent 82 episodes of fast-track warfarin reversal (3 mg intravenous vitamin K 18 to 24 hours before surgery). No patient suffered an adverse reaction to intravenous vitamin K, all but one achieved an International Normalized Ratio ≤1.5 on the day of surgery, and no surgery was deferred. Assays of vitamin K-dependent factor levels pre-and post-vitamin K demonstrated restoration of functional activity to within an acceptable range for surgical haemostasis. While this alternative method requires further validation in a larger prospective randomised study, we have now extended our use of fast-track warfarin reversal using vitamin K to patients with cancer, on the basis of our experience of its safety, convenience, reliability and efficacy.
The vitamin K (VitK) antagonist warfarin is the most commonly employed anticoagulant worldwide 1, 2 . The periprocedural management of warfarin therapy and its cessation remains a common and complex clinical issue 3, 4 .
Historically, the periprocedural management of warfarin therapy has been managed with warfarin cessation five days preoperatively, with or without the addition of parenteral bridging therapy-a rational approach based on consensus opinion 5 . A recent meta-analysis suggested an increased risk of bleeding in the patients who receive bridging anticoagulation 6 ; thus whether to 'bridge' remains a contentious issue. Alternatively, utilising low-dose intravenous VitK (VitK IV ) 12 to 24 hours prior to elective surgery for rapid warfarin reversal has been demonstrated to be safe, efficacious, convenient and reliable by ourselves and others 4, [7] [8] [9] , and avoids the potential need for preoperative heparin bridging 5, 6, 10, 11 .
Our original prospective study of 'fast-track' warfarin reversal (FTWR) was undertaken in a population of general hospital patients undergoing elective surgical procedures 7 . Patients with cancer are at higher risk than non-cancer patients for venous thromboembolism (TE) 12 . This followup study assessed whether our FTWR findings with general patients on chronic anticoagulation with warfarin, who require interruption for the procedure, can be extended to cancer surgery patients.
Materials and methods

Study population and setting
From August 2010 to October 2011, all patients aged ≥18 years on stable long-term warfarin therapy referred to the Peter MacCallum Cancer Centre, East Melbourne, Victoria, for a surgical procedure, regardless of the indication for warfarin or surgical procedure to be performed, were invited to participate. Exclusion criteria were known VitK hypersensitivity or planned neuraxial anaesthesia. Eligible patients were identified at surgery booking or at a preassessment clinic.
Study process (Figure 1)
Ethics approval was obtained from the local Human Research Ethics Committee (Project No.: 13/51L) and informed consent was obtained from all participants. An information leaflet comprehensively outlined the planned process and logistics for the patient, in terms of when to cease warfarin and when (date and time) to attend each phase of the process. All cases were discussed with a haematologist for expert input and decisions regarding the indication for, and dose of, postoperative parenteral bridging anticoagulation 13 . Patients were booked for outpatient administration of VitK IV , the day prior to surgery.
Periprocedural anticoagulation management
Patients were instructed to take their last (usual) dose of warfarin two days prior to surgery. One day prior to surgery warfarin was withheld, patients presented for blood samples, administration of 3 mg VitK IV (rapid IV push) and were monitored for a minimum of 30 minutes for potential infusion-related adverse events. International Normalized Ratio (INR) pre-VitK IV was checked real-time and the haematologist consulted if the INR was >3.0. No patient received preoperative bridging (parenteral) anticoagulation.
On the day of surgery, if the INR was ≤1.5, the patient proceeded with planned surgery. If the INR was >1.5, the anaesthetist, haematologist and surgeon discussed the risks and benefits of proceeding or delaying surgery and/ or whether further administration of VitK IV or plasma-based products was required, with documentation of the process.
Warfarin was recommenced six hours post completion of surgery, unless there were concerns regarding surgical haemostasis, where timing of resumption was determined after discussion between the surgeon, anaesthetist and haematologist. The dose for resumption was the preoperative stable dose unless decided otherwise by the patient's haematologist. Post procedure bridging anticoagulation with low molecular weight heparin (LMWH) was applied based on patient TE risk and, if recommended, was commenced simultaneously with warfarin resumption and continued until a stable, therapeutic INR was achieved. This decision was made by the treating surgical team in conjunction with the haematology team. The doses of LMWH were tailored to TE risk. The postoperative INR was monitored by the surgical team, local medical practitioner or established private pathology warfarin care clinics. Where postoperative bridging was employed, and the patient failed to achieve a therapeutic INR prior to being otherwise ready for hospital discharge, the institution's 'hospital in the home' service provided domiciliary injection of LMWH.
Postoperative monitoring
Periprocedural bleeding and TE (venous and arterial) were monitored clinically, during the inpatient stay and in subsequent outpatient reviews. The timing and duration of follow-up coincided with standard postoperative care. Further investigations (pathology, radiology or echocardiography) were arranged according to clinical indication.
Blood samples
Patients had blood collected pre-and post-VitK IV for real-time INR, and plasma was stored (n=50) for later assessment of VitK-dependent clotting factor levels. Samples were collected using a Sarstedt (Nümbrecht, Germany) monovette system into 3. were double-spun and frozen (-80 o C). Prothrombin time and INR derivation was derived using Neoplastin Plus (coagulometer-specific international sensitivity index 1.31). Factors II, VII, and X were measured by a prothrombin timebased one stage clot activity method; FIX was measured using an activated partial thromboplastin-based assay, with commercial factor-depleted human plasmas and a four-point standard calibration curve.
Data collection
Data were collected at clinical reviews and from electronic patient records and included demographics, medical and cancer history, indication for anticoagulation, type of surgical procedure, presence/absence of bridging therapy, periprocedural complications, pathology results, diagnostic imaging and blood product utilisation.
Outcomes
Primary outcomes were: • efficacy of low-dose VitK IV for short-term warfarin reversal prior to elective invasive procedures, as assessed by INR values one hour preprocedure and the ability to proceed to surgery without delay, and • adverse reactions to VitK IV . Secondary outcomes were: • protocol adherence, • impact of warfarin therapy and subsequent reversal with low-dose VitK IV on plasma levels of VitK-dependent factors (II, VII, IX and X), • incidence of perioperative bridging anticoagulation requirement, • clinically detected thrombotic/thromboembolic complication rate, and • rate of clinically significant bleeding (major and minor) as defined previously 14 .
Statistical analysis
Baseline patient characteristics, INR and VitK-dependent factor levels are presented using descriptive statistical tools. Median (range) was utilised for continuous variables. Counts and percentages were used for categorical data.
Results
Patient characteristics
During the study period, 71 patients fulfilled eligibility criteria and underwent 82 episodes of FTWR (some patients had two or more surgical procedures). Only one eligible patient was not included in the study due to clinician preference to withhold warfarin for five days prior to surgery. No surgical procedures or indications for warfarin therapy were excluded from enrolment.
For the patient cohort, median age was 76 (range 24 to 88) years, and 61 (73%) were male. The most common indication for warfarin was atrial fibrillation (n=48, 59%), six of whom had an additional indication. Median CHADS score was 2.5 (range 0 to 5) 15 . Fifteen (18%) had had prior TE, six (7%) had a mechanical mitral valve replacement and eight (10%) had a mechanical or tissue aortic valve replacement.
For the purposes of the analyses, each episode of FTWR (as opposed to each patient) was considered an event within the cohort and therefore a denominator of 82 was used ( Table 1) .
Vitamin K safety and efficacy
No patient suffered an adverse reaction to the administration of VitK IV . The median INR post VitK IV (i.e. on the day of surgery) was 1.2 (1.0 to 1.8) ( Table 2 ). All patients proceeded to surgery as scheduled. Only one patient had an INR >1.5 (1.8) . This patient was scheduled for a wide local excision of melanoma and, after discussion, surgery was undertaken without complication. The median INR immediately prior to VitK IV one day prior to surgery was 2.24 (1.3 to 3.2), with 53 (64%) of the episodes having an INR of 2.0 or more.
Vitamin K-dependent procoagulant factor activity
A pre-defined sequential cohort of 50 paired platelet-poor plasma samples pre-and post-vitK IV were included in a substudy assessing vitK-dependent factor activity (II, VII, IX and X) ( Figure 2 ). Using standard haemostatic factor activity thresholds for adequacy of haemostasis 19 (II 20% to 40%, IX 25% to 30%, VII and X 10% to 20%), all of the samples tested on the day of surgery had adequate levels.
Perioperative bridging anticoagulation
No patients received preoperative bridging anticoagulation; 37 (45%) received postoperative bridging anticoagulation, of whom 30 (36.5%) were prescribed a therapeutic dosing regimen of enoxaparin (1 mg/kg sc bd) and seven (8.5%) received a standard prophylactic dose (40 mg sc daily). No patients received unfractionated heparin bridging therapy. Those who received therapeutic dosing were regarded as high risk, such as having a mechanical heart valve, recent (<3 months) acute TE, or history of recurrent TE events. Bridging therapy was commenced six hours post procedure as per institutional guidelines. Those whose bridging therapy was delayed due to concerns regarding surgical haemostasis and subsequent bleeding risk, were commenced on enoxaparin the following day (within 24 hours). No patient had discharge delayed due to bridging requirements, as they were discharged with outpatient administration of LMWH arranged.
Bleeding complications
Eight patients (9.7%) experienced clinically significant bleeding, of whom four required red cell transfusion (4.9%). None of the bleeding episodes were considered directly attributable to the FTWR process, and all factor activity level was ≥30% (Table 3) . 
Thrombotic complications
One patient developed a common femoral vein thrombosis, confirmed on postoperative day 12. The patient was being anticoagulated for deep vein thrombosis/pulmonary embolism and had a subtherapeutic INR preoperatively. It was considered likely by the treating team that the patient had existing subclinical thrombosis prior to surgery.
Discussion
The results of this study demonstrate the efficacy of FTWR for perioperative anticoagulation management in surgical patients with cancer. The use of VitK IV achieved an INR <1.5 in all but one FTWR episode, with 100% of surgical procedures proceeding without delay.
No patient developed an adverse event from the rapid infusion of VitK IV , but given the anticipated low rates of reactions (approximately 1 in 5000), the study was not sufficiently powered to detect such outcomes 20 .
Protocol adherence for the study was 100% without significant practical issues encountered.
The restoration of VitK-dependent factors ( Table 2) showed that all patients with an INR ≤1.5 had factor activity of at least 30% to 40%, which is deemed adequate for normal haemostasis 19 .
Although preoperative bridging enoxaparin was avoided in all patients, 45% of patients enrolled were deemed sufficiently high risk to require postoperative parenteral anticoagulant therapy.
The findings of this study support the results of the previous study undertaken in a general patient group of 178 patients, of whom 161 achieved an INR ≤1.5 using the FTWR process 7 . Data from the two studies combined demonstrates a successful VitK reversal rate of 95.3% in 260 patients by using a FTWR strategy.
An important consideration is bleeding complications. In the current cohort, eight patients (9.7%) suffered clinically significant bleeding. Seven of the eight bleeding complications occurred in patients receiving bridging thromboprophylaxis (75% of whom received therapeutic dosing) following procedures inherently at high risk of bleeding. Importantly, of the eight patients with periprocedural bleeding, all had an INR ≤1.4 on the day of (and prior to) surgery and the three who had factor activity measured all had levels >40%, which is considered adequate for surgical haemostasis. This observed rate of clinically significant bleeding was similar to that reported in the PROSPECT trial (a postoperative bleeding rate of up to 20% after major surgery in patients receiving therapeutic dose bridging enoxaparin 21 ), while the recent meta-analysis by Douketis et al, assessing the safety and efficacy of periprocedural bridging heparin, reported rates around 13% in patients receiving bridging therapy 6, 14 . Based on these earlier reports, we interpret the bleeding rate in the LMWH-bridged proportion of our cohort as being comparable to other groups of LMWH-bridged patients. No bleeding complications occurred in our unbridged patients. The bleeding in our cohort was seemingly related to surgical complications in those high-risk patients who also received postoperative bridging, rather than the process of active reversal of warfarin with VitK itself. It is important to acknowledge, however, that this is a small sample of patients, and that, consequently, the ability to detect a bleeding rate that differs from other, larger, published series is limited.
There was no apparent increase of TE despite the inherent high risk in patients with cancer. A single post-surgical event occurred in a patient who had had a recent deep vein thrombosis/pulmonary embolism, and who presented with a subtherapeutic INR one day prior to surgery (INR 1.5), as outlined earlier. No patient suffered arterial TE complications.
Although it is reassuring that an unusually high rate of thromboembolic complications was not present in our cancer patient cohort despite the inherent high risk 12 , given the expected low incidence of such complications, our sample size was too small to adequately define rates of these complications when using FTWR.
Another valid concern regarding the FTWR process is the possibility of warfarin resistance on resumption of oral anticoagulation, potentially prolonging the requirement for postoperative bridging. While this study did not evaluate time to rewarfarinisation, Burbury et al's previous cohort found a median time to achieving a therapeutic INR was four days post warfarin resumption 7 .
Individually, this study is relatively small, single-armed and conducted at a single centre, potentially limiting its external validity. However, including the data from the previous Burbury et al study provides a larger combined cohort, in which the efficacy and reliability of this process was demonstrated consistently and independently at two institutions in two states. The process appears simple and feasible at busy tertiary hospitals, even when treating geographically remote patients.
This process is now established as routine care at both institutions, with excellent collaboration and support from all clinical staff (and patients) involved. Moreover, it has recently been endorsed by local Australian/New Zealand consensus guidelines 4 . Our experience has been that this method has been less complex and labour-intensive compared to traditional warfarin reversal management preoperatively, although many patients still require postoperative bridging therapy. We have not formally collected data on clinician and patient satisfaction and it would be beneficial to address this question in a (planned) phase III randomised trial to compare the safety and efficacy (and cost-effectiveness) of conventional periprocedural warfarin management versus this FTWR approach, at a major tertiary institution. However, our preliminary experience is that patients prefer this process as it is simple, reliable and with less requirement for bridging therapy.
Conclusion
Further validation of this process in a larger prospective randomised study, comparing conventional and FTWR approaches, would be important for scientific and clinical validity. A further study would also allow more precise estimation of rates for rarer events such as TE, clinically significant bleeding and VitK hypersensitivity reactions, as well as a comprehensive assessment of the logistics and costeffectiveness of this approach. In the interim, however, we believe that it is reasonable to adopt FTWR using VitK, given our experience of its convenience, reliability and efficacy.
